pioglitazone glp 1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Decoding GLP-1 Weight Loss Medications

These may include: Nausea Vomiting Diarrhea Constipation Bloating or gas Decreased appetite Fatigue To minimize side effects, its important to start with a lower dose and gradually increase as tolerated

J Biol Chem 2008, 283: 3446934489

Mechanism of Action 5-Amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular methylation and NAD+ metabolism, making it a widely referenced tool in enzymatic and epigenetic research models

1 Check your employer's benefit design first Before searching formularies, ask your HR benefits team whether anti-obesity medications are included in your plan